Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001641172-25-019781
Filing Date
2025-07-15
Accepted
2025-07-15 19:35:19
Documents
1
Period of Report
2025-07-11

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3916
  Complete submission text file 0001641172-25-019781.txt   5576
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Issuer) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E, SUITE 310 SEATTLE WA 98102
Business Address
Kenney Richard T (Reporting) CIK: 0001606653 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35570 | Film No.: 251125967